HANSOH PHARMAC. HD-00001
Research HANSOH PHARMAC. HD-00001 (3KY) on Bullrun: market cap EUR 23.76B, P/E 32.7, dividend yield 1.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker3KY
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 23.76B
- P/E32.7
- Dividend yield1.2%
- Financial periodFY2025
- RevenueCNY 15.03B
- Revenue growth22.6%
- Net incomeCNY 5.56B
- Free cash flowCNY 6.25B
- Gross margin90.0%
Valuation Snapshot
latest market cap is EUR 23.76B; P/E is 32.7; dividend yield is 1.2%.
Peer valuation comparison
Latest P/E is 32.66x versus a Healthcare sector median of 24.46x (33.5% above).
Latest dividend yield is 1.2% versus a Healthcare sector median of 2.11% (43.1% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 15.03B | CNY 5.56B | CNY 6.25B | 90.0% | 0.93 | CNY 31.55B | CNY 105.09M | CNY 35.36B |
| FY2024 | CNY 12.26B | CNY 4.37B | CNY 3.34B | 91.0% | 0.73 | CNY 22.62B | CNY 117.89M | CNY 28.68B |
| FY2023 | CNY 10.10B | CNY 3.28B | CNY 2.75B | 89.8% | 0.52 | CNY 22.43B | CNY 4.30B | CNY 25.79B |
| FY2022 | CNY 9.38B | CNY 2.58B | CNY 2.45B | 90.8% | 0.44 | CNY 17.62B | CNY 4.38B | CNY 22.65B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 23.76B | 32.7 | 1.4% | 0.05 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.05 EUR, yield 1.2%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.04 CNY |
| FY2024 | 0.04 CNY |
| FY2023 | 0.01 CNY |
| FY2022 | 0.02 CNY |
About HANSOH PHARMAC. HD-00001
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is HANSOH PHARMAC. HD-00001's market cap?
HANSOH PHARMAC. HD-00001's market capitalization is EUR 23.76B.
What is HANSOH PHARMAC. HD-00001's P/E ratio?
HANSOH PHARMAC. HD-00001's price-to-earnings (P/E) ratio is 32.7.
Does HANSOH PHARMAC. HD-00001 pay a dividend?
HANSOH PHARMAC. HD-00001 has a dividend yield of 1.2%.
What does HANSOH PHARMAC. HD-00001 do?
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases.